A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

BACKGROUND: The standard 6-month four-drug regimen for the treatment of drug-sensitive tuberculosis has remained unchanged for decades and is inadequate to control the epidemic. Shorter, simpler regimens are urgently needed to defeat what is now the world’s greatest infectious disease killer. METHOD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Med
Main Authors: Phillips, Patrick P. J., Dooley, Kelly E., Gillespie, Stephen H., Heinrich, Norbert, Stout, Jason E., Nahid, Payam, Diacon, Andreas H., Aarnoutse, Rob E., Kibiki, Gibson S., Boeree, Martin J., Hoelscher, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4804526/
https://ncbi.nlm.nih.gov/pubmed/27004726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-016-0597-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados